HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Pharmacology350 papers

Meningococcal infectious disease

Last edited: 4/14/2026

Overview

Meningococcal disease, caused by Neisseria meningitidis, manifests as meningitis, septicaemia, or both, with high mortality and significant morbidity rates, particularly in children and adolescents 418.

Diagnosis

  • Clinical Presentation: Sudden onset of fever, headache, neck stiffness, petechiae, or purpura 15.
  • Laboratory Tests: Blood cultures, cerebrospinal fluid (CSF) analysis (pleocytosis, elevated protein, low glucose) 15.
  • Serology: Identification of N. meningitidis in blood or CSF 15.
  • Procalcitonin: May help rule out meningococcal disease in well-appearing children, though not definitive 13.

    • Management

  • Antibiotics: Immediate parenteral antibiotics (e.g., ceftriaxone, penicillin) 1924.
  • Supportive Care: Fluid resuscitation, inotropic support, mechanical ventilation if needed 2425.
  • Monitoring: Close monitoring for shock, disseminated intravascular coagulation (DIC), and organ failure 2728.
  • Prophylactic Antibiotics: Rifampicin-based prophylaxis for close contacts, noting potential for resistant strains 23.

    • Special Populations

  • Pediatrics: High incidence in young children; prompt recognition and treatment critical 415.
  • Comorbidities: No specific guidelines provided in abstracts; general principles apply 14.

    • Key Recommendations

  • Prompt Antibiotic Administration: Initiate parenteral antibiotics immediately upon suspicion of meningococcal disease to reduce mortality (Evidence: Strong 19).
  • Vaccination Programs: Implement meningococcal B vaccination programs for high-risk age groups (e.g., infants, adolescents) to prevent disease (Evidence: Moderate 12).
  • Monitoring Endotoxin Levels: Consider plasma endotoxin levels to predict severity and complications in systemic meningococcal disease (Evidence: Moderate 2728).
  • Prophylactic Measures: Administer chemoprophylaxis to close contacts, aware of potential rifampicin resistance (Evidence: Weak 23).

    • References

    1 Wheldrake K, Sisnowski J, AHoure M, Anagnostou N, Almond S, Flood L. Surveillance of adverse events following immunisation with meningococcal B vaccine (4CMenB), South Australia, 2018-2022. Vaccine 2025. link 2 Stefanizzi P, Bianchi FP, Spinelli G, Amoruso F, Ancona D, Stella P et al.. Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia Region, 2014-19. Human vaccines & immunotherapeutics 2022. link 3 Perez-Vilar S, Dores GM, Marquez PL, Ng CS, Cano MV, Rastogi A et al.. Safety surveillance of meningococcal group B vaccine (Bexsero®), Vaccine Adverse Event Reporting System, 2015-2018. Vaccine 2022. link 4 Isitt C, Cosgrove CA, Ramsay ME, Ladhani SN. Success of 4CMenB in preventing meningococcal disease: evidence from real-world experience. Archives of disease in childhood 2020. link 5 Myers TR, McNeil MM, Ng CS, Li R, Marquez PL, Moro PL et al.. Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016. Vaccine 2020. link 6 Domingo P, Pomar V, Mauri A, Barquet N. Standing on the shoulders of giants: two centuries of struggle against meningococcal disease. The Lancet. Infectious diseases 2019. link30040-4) 7 Mentzer D, Oberle D, Keller-Stanislawski B. Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2018. link 8 Tseng HF, Sy LS, Ackerson BK, Hechter RC, Tartof SY, Haag M et al.. Safety of Quadrivalent Meningococcal Conjugate Vaccine in 11- to 21-Year-Olds. Pediatrics 2017. link 9 Myers TR, McNeil MM, Ng CS, Li R, Lewis PW, Cano MV. Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015. Vaccine 2017. link 10 Arakaki L, Ngai S, Weiss D. Completeness of Neisseria meningitidis reporting in New York City, 1989-2010. Epidemiology and infection 2016. link 11 Robertson CA, Greenberg DP, Hedrick J, Pichichero M, Decker MD, Saunders M. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine. Vaccine 2016. link 12 Allen LN. Mild meningococcaemia, pyrexia protocols and a problematic public health response. BMJ case reports 2014. link 13 Herd D. Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3: In well-appearing children suspected of meningococcal disease can procalcitonin reduce the need for empiric antibiotic treatment?. Emergency medicine journal : EMJ 2013. link 14 Terranella A, Beekmann SE, Polgreen PM, Cohn A, Wu HM, Clark TA. Practice patterns of infectious disease physicians for management of meningococcal disease. The Pediatric infectious disease journal 2012. link 15 Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine 2012. link 16 Bröker M. Indirect effects by meningococcal vaccines: herd protection versus herd immunity. Human vaccines 2011. link 17 Tatley MV, Kunac DL, McNicholas A, Zhou L, Ballantyne S, Ashton J et al.. The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand. Vaccine 2008. link 18 Meredith, Galwankar S. Clinical and epidemiological implications of meningococcal disease. The Journal of the Association of Physicians of India 2005. link 19 Riordan FA. Improving promptness of antibiotic treatment in meningococcal disease. Emergency medicine journal : EMJ 2001. link 20 Robinson JM, Doughty I, Marshall R, Benson J. Meningococcal disease among children of Indian subcontinent ethnic origin. Lancet (London, England) 2000. link02358-8) 21 . Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports 2000. link 22 Winrow AP. Abdominal pain as an atypical presentation of meningococcaemia. Journal of accident & emergency medicine 1999. link 23 Dawson SJ, Fey RE, McNulty CA. Meningococcal disease in siblings caused by rifampicin sensitive and rifampicin resistant strains. Communicable disease and public health 1999. link 24 Moore E, Healy N. Nursing perspectives in meningococcal disease. Intensive & critical care nursing 1998. link80240-1) 25 Leeman J, Pierard D, Huyghens L. Different clinical manifestations of meningococcaemia: three patient reports. European journal of emergency medicine : official journal of the European Society for Emergency Medicine 1996. link 26 Broome CV. Vaccine efficacy determination. NIPH annals 1991. link 27 Brandtzaeg P, Sandset PM, Joø GB, Ovstebø R, Abildgaard U, Kierulf P. The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thrombosis research 1989. link90054-6) 28 Brandtzaeg P, Kierulf P, Gaustad P, Skulberg A, Bruun JN, Halvorsen S et al.. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. The Journal of infectious diseases 1989. link 29 Brandtzaeg P, Kierulf P, Gaustad P, Dobloug J, Mollnes TE, Sirnes K. Systemic meningococcal disease: a model infection to study acute endotoxinemia in man. Progress in clinical and biological research 1988. link 30 Conte JE. The clinical spectrum of meningococcal disease. California medicine 1970. link

    Original source

    1. [1]
      Surveillance of adverse events following immunisation with meningococcal B vaccine (4CMenB), South Australia, 2018-2022. — Wheldrake K, Sisnowski J, AHoure M, Anagnostou N, Almond S, Flood L Vaccine (2025)
    2. [2]
      Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia Region, 2014-19. — Stefanizzi P, Bianchi FP, Spinelli G, Amoruso F, Ancona D, Stella P et al. Human vaccines & immunotherapeutics (2022)
    3. [3]
      Safety surveillance of meningococcal group B vaccine (Bexsero®), Vaccine Adverse Event Reporting System, 2015-2018. — Perez-Vilar S, Dores GM, Marquez PL, Ng CS, Cano MV, Rastogi A et al. Vaccine (2022)
    4. [4]
      Success of 4CMenB in preventing meningococcal disease: evidence from real-world experience. — Isitt C, Cosgrove CA, Ramsay ME, Ladhani SN Archives of disease in childhood (2020)
    5. [5]
      Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016. — Myers TR, McNeil MM, Ng CS, Li R, Marquez PL, Moro PL et al. Vaccine (2020)
    6. [6]
      Standing on the shoulders of giants: two centuries of struggle against meningococcal disease. — Domingo P, Pomar V, Mauri A, Barquet N The Lancet. Infectious diseases (2019)
    7. [7]
      Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016. — Mentzer D, Oberle D, Keller-Stanislawski B Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin (2018)
    8. [8]
      Safety of Quadrivalent Meningococcal Conjugate Vaccine in 11- to 21-Year-Olds. — Tseng HF, Sy LS, Ackerson BK, Hechter RC, Tartof SY, Haag M et al. Pediatrics (2017)
    9. [9]
      Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015. — Myers TR, McNeil MM, Ng CS, Li R, Lewis PW, Cano MV Vaccine (2017)
    10. [10]
      Completeness of Neisseria meningitidis reporting in New York City, 1989-2010. — Arakaki L, Ngai S, Weiss D Epidemiology and infection (2016)
    11. [11]
      Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine. — Robertson CA, Greenberg DP, Hedrick J, Pichichero M, Decker MD, Saunders M Vaccine (2016)
    12. [12]
      Mild meningococcaemia, pyrexia protocols and a problematic public health response. — Allen LN BMJ case reports (2014)
    13. [13]
      Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3: In well-appearing children suspected of meningococcal disease can procalcitonin reduce the need for empiric antibiotic treatment? — Herd D Emergency medicine journal : EMJ (2013)
    14. [14]
      Practice patterns of infectious disease physicians for management of meningococcal disease. — Terranella A, Beekmann SE, Polgreen PM, Cohn A, Wu HM, Clark TA The Pediatric infectious disease journal (2012)
    15. [15]
      Meningococcal disease: clinical presentation and sequelae. — Pace D, Pollard AJ Vaccine (2012)
    16. [16]
      Indirect effects by meningococcal vaccines: herd protection versus herd immunity. — Bröker M Human vaccines (2011)
    17. [17]
      The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand. — Tatley MV, Kunac DL, McNicholas A, Zhou L, Ballantyne S, Ashton J et al. Vaccine (2008)
    18. [18]
      Clinical and epidemiological implications of meningococcal disease. — Meredith, Galwankar S The Journal of the Association of Physicians of India (2005)
    19. [19]
      Improving promptness of antibiotic treatment in meningococcal disease. — Riordan FA Emergency medicine journal : EMJ (2001)
    20. [20]
      Meningococcal disease among children of Indian subcontinent ethnic origin. — Robinson JM, Doughty I, Marshall R, Benson J Lancet (London, England) (2000)
    21. [21]
      Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports (2000)
    22. [22]
      Abdominal pain as an atypical presentation of meningococcaemia. — Winrow AP Journal of accident & emergency medicine (1999)
    23. [23]
      Meningococcal disease in siblings caused by rifampicin sensitive and rifampicin resistant strains. — Dawson SJ, Fey RE, McNulty CA Communicable disease and public health (1999)
    24. [24]
      Nursing perspectives in meningococcal disease. — Moore E, Healy N Intensive & critical care nursing (1998)
    25. [25]
      Different clinical manifestations of meningococcaemia: three patient reports. — Leeman J, Pierard D, Huyghens L European journal of emergency medicine : official journal of the European Society for Emergency Medicine (1996)
    26. [26]
      Vaccine efficacy determination. — Broome CV NIPH annals (1991)
    27. [27]
      The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. — Brandtzaeg P, Sandset PM, Joø GB, Ovstebø R, Abildgaard U, Kierulf P Thrombosis research (1989)
    28. [28]
      Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. — Brandtzaeg P, Kierulf P, Gaustad P, Skulberg A, Bruun JN, Halvorsen S et al. The Journal of infectious diseases (1989)
    29. [29]
      Systemic meningococcal disease: a model infection to study acute endotoxinemia in man. — Brandtzaeg P, Kierulf P, Gaustad P, Dobloug J, Mollnes TE, Sirnes K Progress in clinical and biological research (1988)
    30. [30]
      The clinical spectrum of meningococcal disease. — Conte JE California medicine (1970)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG